Literature DB >> 11672509

Ectopic expression of CCAAT/enhancer binding protein beta (C/EBPbeta) in long-term bone marrow cultures induces granulopoiesis and alters stromal cell function.

P M Popernack1, L T Truong, M Kamphuis, A J Henderson.   

Abstract

CCAAT/enhancer binding proteins (C/EBP) have been demonstrated to impact directly the development of multiple hematopoietic lineages. However, the role of C/EBPbeta in the differentiation of various hematopoietic lineages has not been thoroughly examined. We used primary bone marrow cultures to assess directly the ability of C/EBPbeta to influence myelopoiesis. Retroviral expression vectors were used to express C/EBPbeta ectopically in murine primary long-term bone marrow cultures. The differentiation potential of these cells was determined using hematopoietic colony assays and differential staining of cells within the cultures. Bone marrow cultures that overexpressed C/EBPbeta had fewer myeloid progenitors and a significant increase in the number of granulocytes. The ability of C/EBPbeta to alter hematopoiesis in vitro was dependent on the presence of the transcriptional activation domain because LIP, which lacks this functional domain, did not decrease the ability of bone marrow cultures to support myeloid progenitors. These data also show that C/EBPbeta influences hematopoiesis by altering stromal cell function rather than the intrinsic developmental potential of myeloid progenitor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672509     DOI: 10.1089/152581601753193841

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  8 in total

1.  C/EBPβ and CHOP participate in tanshinone IIA-induced differentiation and apoptosis of acute promyelocytic leukemia cells in vitro.

Authors:  Kaiji Zhang; Jian Li; Wentong Meng; Hongyun Xing; Yiming Yang
Journal:  Int J Hematol       Date:  2010-10-28       Impact factor: 2.490

Review 2.  Regulation of monocyte differentiation by specific signaling modules and associated transcription factor networks.

Authors:  René Huber; Daniel Pietsch; Johannes Günther; Bastian Welz; Nico Vogt; Korbinian Brand
Journal:  Cell Mol Life Sci       Date:  2013-03-24       Impact factor: 9.261

3.  C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.

Authors:  Meritxell Alberich-Jordà; Bas Wouters; Martin Balastik; Clara Shapiro-Koss; Hong Zhang; Annalisa Di Ruscio; Annalisa DiRuscio; Hanna S Radomska; Alexander K Ebralidze; Giovanni Amabile; Min Ye; Junyan Zhang; Irene Lowers; Roberto Avellino; Ari Melnick; Maria E Figueroa; Peter J M Valk; Ruud Delwel; Daniel G Tenen
Journal:  J Clin Invest       Date:  2012-11-19       Impact factor: 14.808

4.  C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells.

Authors:  Estelle Duprez; Katharina Wagner; Heike Koch; Daniel G Tenen
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

5.  Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation.

Authors:  Melanie Wurm; John Kowalski; Dirk Heckl; Xiao-Bing Zhang; Veronica Nelson; Brian C Beard; Hans-Peter Kiem
Journal:  Exp Hematol       Date:  2013-10-26       Impact factor: 3.084

6.  Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology.

Authors:  Emily I Chen; Katherine D Crew; Meghna Trivedi; Danielle Awad; Mathew Maurer; Kevin Kalinsky; Antonius Koller; Purvi Patel; Jenny Kim Kim; Dawn L Hershman
Journal:  PLoS One       Date:  2015-12-28       Impact factor: 3.240

Review 7.  The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function.

Authors:  Wenxin Wang; Xueli Xia; Lingxiang Mao; Shengjun Wang
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

Review 8.  Tanshinones: sources, pharmacokinetics and anti-cancer activities.

Authors:  Yong Zhang; Peixin Jiang; Min Ye; Sung-Hoon Kim; Cheng Jiang; Junxuan Lü
Journal:  Int J Mol Sci       Date:  2012-10-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.